Hydreight Technologies Inc (NURS) Fair Value & Analysis
Healthcare · CA · Market cap C$219M
Fair value as of: Jun 24, 2026
Analysis
Hydreight Technologies Inc (NURS) currently trades at C$4.31, while our model-based Fair Value estimate is C$0.6900 — implying the stock looks roughly 84.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Hydreight Technologies Inc. operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application. It also provides consulting and advice in setting up health and wellness services, including assistance with finding experienced advisors in the areas of medical and privacy law, among others; medical liability insurance; pharmaceutical IV programs vetted by duly licensed pharmacists; procedural guides with respect to various services, such as a range of IV therapy treatments, GLP1, NAD, Botox, and fillers; and hiring, on-boarding, training, marketing, branding, payroll, and other accounting services. In addition, the company offers an online pharmacy, which allows its network of medical practitioners to purchase pharmacy products from federally regulated pharmacies. Hydreight Technologies Inc. is headquartered in Las …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Hydreight Technologies Inc (NURS) undervalued?
What is the fair value of NURS?
What is the quality score of NURS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.